Psychosocial interventions and medication adherence in bipolar disorder by Depp, Colin A. et al.
he functional consequences of bipolar disorder are
staggering.Bipolar disorder is the sixth leading cause of
years lost to disability among all medical conditions,
according to the World Health Organization.
1The annual
costs of treating bipolar disorder are estimated at 45 billion
dollars per year.Employed people with bipolar disorder
experience about 65 lost work days per year,more than
double than that of people with major depression,
2 and
patients report a high degree of other psychosocial impair-
ments in large cross-national surveys.
3Approximately 10%
of people with bipolar disorder die by suicide—among the
highest rates of any psychiatric disorder. To attempt to
reduce the severity of this disability, psychosocial inter-
ventions have served as a complement to pharmacother-
apy for many years. However, structured augmentative
psychosocial interventions for bipolar disorder have only
recently been empirically evaluated in large,randomized,
controlled clinical trials. The theoretical and practical
approaches in these interventions vary. However, the
enhancement of adherence to mood-stabilizing medica-
tions is a common goal to nearly all of them,as adherence
generally serves as a foundation for rehabilitation strate-
gies,and nonadherence is a risk factor for multiple nega-
tive outcomes (eg,hospitalization).
In the following review, we describe the current
approaches to psychotherapeutic interventions in bipo-
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Recent research has indicated that psychosocial interven-
tions can have a valuable role in reducing the substantial
psychosocial disability associated with bipolar disorder.
Randomized controlled trials of these interventions indi-
cate that improvements are seen in symptoms, psychoso-
cial functioning, and treatment adherence. These inter-
ventions, systematically presented in the form of
standardized treatment manuals, vary in format, duration,
and theoretical basis. All are meant to augment pharma-
cotherapy, which represents the standard of treatment in
the field. Modalities that have gathered the most empir-
ical support include cognitive-behavioral therapy, family-
focused therapy, interpersonal and social rhythms therapy,
and psychoeducation. The enhancement of adherence to
pharmacotherapy is a common therapeutic target, due to
the association of nonadherence with higher relapse rates,
hospitalization, and health care costs among people with
bipolar disorder. Given the complexity of nonadherence
behavior, multicomponent interventions are often
required. In this review, we provide an overview of the
rationale, evidence base, and major psychotherapeutic
approaches in bipolar disorder, focusing on the assessment
and enhancement of medication adherence. 
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:239-250.lar disorder and the evidence for their effectiveness,with
a focus on methods for enhancing adherence to psy-
chopharmacological treatment for bipolar disorder.Our
review is based on a literature search through PubMed,
google.scholar.com, and PsycINFO, from which we
selected English-language articles published in peer-
reviewed journals published after 1990 describing psy-
chosocial interventions for bipolar disorder and medica-
tion adherence.
Emergence of psychotherapy
There are a number of hypothesized reasons as to why
psychotherapy was not a widely accepted component of
treatment recommendations for bipolar disorder until
recent years.The disorder was thought to have a biolog-
ical diathesis, given the evidence for its heritability.
Therefore,it was assumed that modifying the course of
the illness would be difficult through behavioral and
environmental means. Another reason for the lack of
study of psychotherapy for bipolar disorder was the
belief that attainment of interepisode recovery was
largely achievable through pharmacotherapy;that is,pro-
vided that individuals adhered to mood stabilizers,acute
manic or depressive episodes could be resolved,and the
return to a state at or near to premorbid functioning
could be expected. According to Kraeplin,
4 this
interepisode recovery was among the primary differen-
tiating features of “manic depression”from schizophre-
nia, the latter diagnosis was assumed to follow a pro-
gressive deteriorating and chronic course.Lithium was
heralded as a breakthrough medication,and it was held
that it would produce a high probability of prophylaxis
against mania,which was thought to the most important
therapeutic target of the illness in comparison with bipo-
lar depression.
However,research connecting stressful life events and
other perturbations to episode onset (eg,disruptions to
sleep/wake cycles) suggested that environmental factors
could modify the course of the illness (eg,the “kindling”
model)
5,6 and,subsequently,that there were potentially
modifiable aspects of bipolar disorder.In addition,the
evidence from longitudinal prospective studies suggested
that interepisode recovery was far less common than pre-
viously thought,even among individuals receiving state-
of-the-art pharmacotherapy.
7,8 Naturalistic prospective
studies sponsored by the National Institute of Mental
Health’s Collaborative Depression Study
7,9 and the
Stanley Foundation Research Network
10 indicated that,
when symptoms were monitored on a weekly basis,most
people with bipolar disorder spent most of the time expe-
riencing some level of psychiatric symptoms and related
functional impairment.Furthermore,the functional con-
sequences of bipolar disorder were quantified and com-
pared with other chronic mental and physical illnesses,
and this research strongly indicated that the impact of
bipolar disorder on employment and other psychosocial
domains was severe and enduring.
8,11,12
Longitudinal research also indicated that bipolar depres-
sion is, on average, the most typical state and the most
disabling aspect of the illness,compared with mania.The
pharmacologic treatment of bipolar depression is a long-
standing clinical controversy,with concerns over antide-
pressant-associated switch to mania coupled with limited
efficacy of mood stabilizers in preventing or reducing
bipolar depressive episodes.
13 Psychosocial interventions
have been used effectively to treat unipolar depression
for many years,without concerns over side effects.
The above factors provide a strong rationale for adjunc-
tive psychosocial treatment in bipolar disorder.Over the
past two decades, there have been a number of psy-
chotherapeutic modalities specifically developed for the
treatment of bipolar disorder.These therapies include
cognitive behavioral therapy (CBT),interpersonal and
social rhythms therapy (IPSRT),family-focused therapy
(FFT),and psychoeducation.We will describe in greater
detail these specific models (we elected not to discuss
marital therapy or intervention for dually diagnosed indi-
viduals).
All of these psychotherapeutic modalities are intended
to augment, not replace, pharmacotherapy. Each has
been manualized,and each has been evaluated in at least
one randomized controlled clinical trial.However,the
theoretical basis and format of the therapies differ in a
number of ways.These interventions vary in intensity
(ranging from 3 to 25+ sessions),whether interventions
are delivered to individuals,groups,or families,and what
the therapeutic targets are. As with medication, psy-
chosocial interventions can be assessed for their ability
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Selected abbreviations and acronyms
CBT cognitive behavioral therapy
FFT family focused therapy
IPSRT interpersonal and social rhythms therapy
STEP-BD Systematic Treatment Enhancement Program for
Bipolar Disordersto reduce symptoms of mania or depression, for their
ability to prolong remission from active episodes, and
improve ancillary outcomes such as medication adher-
ence and psychosocial functioning.
Perhaps the most compelling evidence in favor of psy-
chotherapy’s effectiveness in bipolar disorder has come
from the recently completed National Institute of Mental
Health sponsored multisite effectiveness trial on the
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD).
14Within this large multisite prac-
tical trial,293 participants with either bipolar disorder I
or II,experiencing active depressive episodes were ran-
domized to one of three intensive psychosocial inter-
ventions (CBT,IPSRT,or FFT) or to a control condition
consisting of a three-session collaborative care interven-
tion.Over 1 year,participants in the intensive conditions
had a higher probability of recovery.A total of 64% in
the intensive conditions vs 52% in collaborative care
intervention attained recovery from depression, along
with a experiencing a briefer median time to recovery
(113 days vs 146 days).Greater improvement on a stan-
dardized measure of psychosocial functioning was also
seen.
15 Interestingly,in secondary analyses,there was lit-
tle distinction in effectiveness between the three inten-
sive conditions.However,we will briefly describe the the-
oretical model and structure of these therapies, along
with how adherence is integrated into their content.
Cognitive behavioral therapy
Adapted from the core components of cognitive therapy
for depression,cognitive therapy for bipolar disorder has
been evaluated in a number of open and randomized
controlled trials,including the STEP-BD study described
above.
16-18These therapies typically last from 20 to 25 ses-
sions, and are delivered in individual or group format.
Activities in CBT for bipolar disorder include self-mon-
itoring of moods and cognitions,addressing dysfunctional
beliefs,and implementing healthier thinking patterns.The
theoretical model undergirding CBT for bipolar depres-
sion is quite similar to that employed in unipolar depres-
sion—reducing and replacing cognitive distortions cou-
pled with behavioral activation. The prevention of
hypomania and mania is accomplished through reduction
in impulsive behaviors,by teaching attention to exces-
sively goal-oriented thoughts and destabilizing behaviors
(eg,working around the clock on a new project).
Addressing adherence and beliefs about bipolar disorder
is accomplished through examining attitudes and beliefs
about medications.For example,the decisional balance
is a cognitive task that is frequently used to elucidate the
benefits and drawbacks for taking medications or not
taking them (in a 2X2 matrix).The aim of this task is to
highlight the potential risks of not taking medications,
and to identify modifiable aspects of the drawbacks of
taking medications (eg, weight gain).As described by
Newman and colleagues, the goal of CBT in regard to
adherence is to help the individual to “make peace”with
medication.
16The largest clinical trials in CBT for bipo-
lar disorder have occurred in the United Kingdom.In a
study conducted by Lam et al,CBT was positively asso-
ciated with relapse prevention in a single-site random-
ized controlled trial with euthymic patients.
19 However,
in a large multisite “pragmatic’ trial which enrolled 253
patients in noneuthymic states,Scott et al
20 found little
effect of CBT compared with a treatment as usual con-
dition,except for those patients with shorter duration of
illness.
Interpersonal and social rhythms therapy 
IPSRT integrates interpersonal therapy with a behavioral
component focusing on enhancing routine and structure
of day-to-day events.
21,22 The theory emerged from
research indicating that disruptions in social rhythms,
such as interpersonal conflicts, effectively destabilized
bipolar illness and the timing of daily activities.The ther-
apeutic approach is individualized,and involves educa-
tion about bipolar disorder,tracking and stabilizing daily
events, and the psychodynamic interpersonal therapy
component that is an evidence-based treatment for
unipolar depression. The social rhythm component
includes monitoring of daily routines (eg,time of awak-
ening) with a tool called the Social Rhythm Metric,
23 and
targeting stability in the timing of these routines.
Medication adherence in IPSRT is typically addressed
through education about bipolar disorder;however,the
routinization of daily life also may include taking med-
ications at structured times of the day,which may,in turn
reduce the frequency of unintentional nonadherence.In
addition to the STEP-BD study,there has been one other
clinical trial comparing IPSRT with an intensive clinical
management intervention.
22,24There were few immediate
differences between conditions on symptoms,
22 but an
advantage in relapse prevention for IPSRT was seen at 2
years post-treatment.
24
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FFT was developed out of research on the role of
expressed emotion in relapse in people with schizophre-
nia—in particular that interpersonal conflict and hostil-
ity are important disruptors representing the “stress”in
the stress-vulnerability model of bipolar disorder.The
goals of FFT are to enhance communication skills among
family members,and increase supportive behaviors,along
with increasing problem-solving behaviors.
25There is a
sequence of three modules:(i) psychoeducation,(ii) com-
munication training,7 to 10 sessions,and (iii) problem-
solving training,4 to 5 sessions.Prior to its evaluation in
the STEP-BD study,Miklowitz et al found that FFT in
comparison with a brief clinical management interven-
tion showed longer survival intervals in terms of duration
of remission along with improvements in adherence.The
impact of FFT on adherence was posited to revolve
around the depiction of bipolar disorder as a biological
illness that is treatable,and that family involvement and
“buy-in”to this model increased the family unit's atten-
dance to medication adherence as a desired and shared
goal.
Psychoeducation
Psychoeducation has been evaluated in clinical trials in
Europe and in large health care systems in the United
States.The content and intensity of these interventions
vary.Psychoeducation can be delivered in a group format
or individually.Session length ranges from three sessions
to upwards of 20 sessions.
26The content of psychoeduca-
tional interventions is generally in the development of
self-management skills in coping with the illness,through
providing education about the disorder and the impor-
tance of adherence,developing skills in identifying early
warning signs,and avoiding dangerous activities such as
substance abuse.
27,28 Participants are taught to monitor
their moods using charts,recognize early warning signs
of episode onset (eg, reduced sleep, irritability), and
engage in action steps in effort to stave off full-blown
mania or depression.
The effectiveness of these interventions has been evalu-
ated in several large studies in the United States and
Europe.In the United States,two multisite intervention
trials have incorporated the Life Goals intervention into
the chronic care approach, one in a private insurance
population
29 and the other in a Veteran’s administration
population.
30 Interestingly,the intervention appeared to
have greater effectiveness in reducing manic rather than
depressive symptoms in the private insurance population
study.
31 In Spain,Colom et al evaluated a 21-session psy-
choeducational program and found improvement in
terms of recurrences,time to depressive,hypomanic,and
manic episodes,and in hospitalization rates.
26A tentative
conclusion from the various studies on psychoeducation
is that a longer duration of treatment strengthens effects,
although a longer duration of treatment is also likely
associated with higher rates of attrition.
Summary of psychosocial modalities
A number of tentative conclusions can be drawn from
the rapidly growing body of research.First,it appears as
though augmentative psychotherapy for bipolar disorder
is feasible and implementable among people in various
clinical states.As the practical trial in the STEP-BD study
indicated,patients need not be in euthymic states or free
of comorbidities to benefit from psychosocial treatment.
Second,although not all trials have been positive,there
is compelling evidence that psychotherapies can be ben-
eficial in augmenting standard pharmacotherapy in bipo-
lar disorder in terms of symptom reduction,episode pro-
phylaxis, and improvement of adherence and
psychosocial functioning.Third,there is some evidence,
rather surprisingly,that these interventions are better at
delaying the onset of mania than in addressing the active
symptoms of depression (the STEP-BD study targeting
bipolar depression is a notable exception).
The next evolution of clinical research on psychotherapy
for bipolar disorder would need to address: (i) which
intervention works best for which patients;(ii) how these
interventions can be made available outside of academic
medical centers;and (iii) what the essential ingredients
of psychotherapy for bipolar disorder are.Bipolar disor-
der is an enormously heterogeneous condition,and it is
highly likely that therapies would need to target sub-
groups of people with bipolar disorder to be adequately
personalized. Presently, there are few evidence-based
moderators or mediators of treatment effectiveness in
bipolar disorder.In their negative trial of CBT for bipo-
lar disorder,Scott et al
20 found that individuals with fewer
previous episodes appeared to derive benefit from treat-
ment, whereas those who had more episodes did not.
Although these kinds of mediators require replication
over multiple studies,it will be important to understand
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with psychotherapy.In addition to clinical variables that
might moderate outcome,whether and how interventions
are accepted and experienced in different ethnic groups
deserves study.In psychosocial interventions for other
conditions,major efforts have been undertaken to adapt
psychosocial treatments to culture-based preferences and
values.There are also efforts under way to modify the
above intervention modalities to address subgroups of
people with bipolar disorder,such as those with chronic
physical illnesses.
32
In addition,understanding how these interventions can
be successfully transported to community settings is a
needed next step.While approximately half of the STEP-
BD sample had attended counseling or psychotherapy in
the community prior to their enrolment,
33 it is doubtful
that many have access to the evidence-based psy-
chotherapies described above.It is also unlikely,due to
financing and staffing limitations,that 20-session pack-
ages,as implemented in the research studies cited above,
will be feasible in many settings.A few multisite studies
have examined how psychosocial interventions that are
considerably less intensive than the STEP-BD interven-
tions can be incorporated into a chronic care model
approach in large health care settings (ie,the Veteran’s
Administration and a large Health Maintenance
Organization),guided by an understanding of the orga-
nizational barriers and facilitators to implementation.
34
Finally,the active ingredients of bipolar psychotherapy
are difficult to ascertain.There are few or no identified
differences in effectiveness between the modalities
described above and,thus far,there have been no “dis-
mantling” studies as have been conducted in psy-
chotherapy for depression.Among the most often men-
tioned candidates as an active ingredient (and
therapeutic outcome) is the enhancement of medication
adherence.In the next section,we will briefly review the
literature on medication adherence in bipolar disorder
and we will present a model to enhance it.
Focus on medication adherence
The therapeutic approaches described above are diver-
gent in their methods to a certain extent, but each
involves education about bipolar disorder and its treat-
ment, and each has some content oriented toward
enhancing medication adherence.Nonadherence is likely
one of the greatest reasons why medications may not
work as well in the community as they do in efficacy
studies evaluating pharmacotherapy.
35 Of course,adher-
ence,in and of itself,is not a guarantee of good outcome,
but medication remains the backbone of treatment for
most people with bipolar disorder.
Suboptimal adherence to medications for bipolar disor-
der is common.Estimates for the prevalence of nonad-
herence in bipolar disorder vary greatly by study popu-
lation and instruments used to assess adherence.
However,it is estimated that 20% to 60%,with a mean
of 40%,of individuals with bipolar disorder are nonad-
herent to prescribed medications at any given time.
36A
longitudinal study found that,among people who initi-
ated lithium,the median time to discontinuation was only
76 days.
37 In that same study,the probability of hospital-
ization was twice as high among discontinuers versus
continuers.Other studies have indicated that the conse-
quences of nonadherence in bipolar disorder include
greater propensity to relapse,higher hospitalization rates,
and greater health care costs.
36,38,39
Types of nonadherence
Nonadherence is a complex phenomenon with a variety
of distinctions and risk factors.There no is definition as
to what the optimal level of adherence is in bipolar dis-
order,as there is in pharmacotherapy for the infectious
diseases (eg,HIV).Furthermore,nonadherence is a not
a unitary or steady state phenomenon;nonadherence can
be intermittent or continuous,and it can be specific to a
single medication or to multiple medications.Moreover,
nonadherence may be voluntary,such as deliberately not
taking medication due to perceptions about its ineffec-
tiveness, or it can be involuntary, such as forgetting or
misinterpreting instructions. Nonadherence may also
involve consuming too much medication. In a study
examining service utilization among San Diego County
public mental health clients with schizophrenia, the
group with highest health care costs were those who were
“overfillers” of antipsychotic medications, rather than
“underfillers.”
40
Assessing nonadherence
In addition to its definition,the mode of measurement of
nonadherence is also challenging, as there is no “gold
standard.”The choices of measurement strategies include
self-report, pill counts, blood level, or microelectronic
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243devices.Subjective measures of adherence,such as self-
report,offer probably the most convenient measure of
adherence,although numerous studies in bipolar disor-
der or in other chronic illnesses have shown that they are
subject to underestimation of actual rates of nonadher-
ence. Caregiver reports may be less subject to under-
reporting biases,yet a substantial proportion of people
with bipolar disorder do not have caregivers who are
aware of the individual’s daily intake of medications.
More objective measures include pharmacy records,
blood levels,and direct pill counts.The degree of differ-
ence in days between successive actual and prescribed
refill dates identifies individuals who have taken fewer
pills than prescribed; the outcome derived from these
analyses include the Cumulative Gap Ratio or the Mean
Possession Ratio.
41The disadvantage of pharmacy data is
that it must be intuited that refills completed on time
equate to taking the medication,and time between refills
is often over the course of months.Blood levels and pill
counts are more direct measures of adherence,but unless
they are a part of routine clinical care,they are impracti-
cal in many clinical and research settings.Furthermore,
it still is possible to “fake”either of these measures,such
as by throwing pills away in the case of pill counts or in
taking medication on the day of the blood test.A newer
technology, Micro Electronic Monitoring Systems
(MEMS),involves tiny sensors placed in pill bottles that
record a time stamp upon opening the bottle.These units
are costly and may be impractical in a clinical setting,par-
ticularly among people with multiple medications to
track.
Generally,the best approach to measuring adherence in
both clinical and research settings is the use of multiple
measures to converge on an estimate of adherence.By
combining information from multiple measures,it is pos-
sible to form a composite measure of adherence by aver-
aging,or by using the adherence measure with the low-
est estimate of adherence. In patients with HIV,
algorithms for deriving an estimate of adherence from
multiple sources have been developed.
42
There are ancillary measures that help to identify the
processes involved in nonadherence.Performance-based
measures do not address medication adherence directly,
however,they measure medication management ability
in a controlled setting. The Medication Management
Ability Assessment
43 is an example of this kind of mea-
sure; it entails a mock medication regimen that the
respondent is told to arrange the medications as they
would in their daily life.Errors on this test can identify
individuals who are at risk for unintentional nonadher-
ence,along with the pattern of the errors.Attitudes and
beliefs about medication,as well as satisfaction with med-
ications,are also important covariates of nonadherence;
an example of self-report measures addressing these con-
struct is the Drug Attitude Inventory
44 and the Brief
Evaluation of Medications Attitudes and Beliefs.
45
Another useful assessment tool is the AIDS Clinical
Trials Group’s Adherence Measure,
46 which includes a set
of questions about reasons for nonadherence.Gathering
the individual’s perspective about what causes nonad-
herence behaviors can be essential to formulating an
intervention strategy.
Risk factors for nonadherence
There are multiple and interacting risk factors for med-
ication nonadherence,with no single profile for high risk
for nonadherence. Conceptually, these can be divided
into patient-related, medication-related, and provider-
related risk factors.
47 Most research has been focused on
patient-related risk factors.
48Among patient characteris-
tics that appear to be risk factors for nonadherence,the
strongest support appears to be for comorbid substance
use, younger age, lower education level, and cognitive
impairment.
Additionally,attitudinal factors,particularly the denial of
the need for medications/severity of the illness appear to
account for a substantial proportion of variance in adher-
ence.
49 In the Health Beliefs Model,an individual is likely
to engage in a behavior,such as adherence,if they believe
their condition is severe enough to warrant treatment,if
the perceived benefits of treatment outweigh the draw-
backs,and if cues to action are provided to initiate and
maintain the behavior. It is likely that these factors
change over the course of the illness.In the early stages,
acceptance of the illness is lower and avoidance coping
is higher,
50 potentially accounting for the relationship
found between younger age and worse adherence.In our
work with older adults,we have hypothesized that cog-
nitive impairment and increasing medication burden may
heighten the importance of cues to action in maintaining
adherence.
51
Medication-related risk factors are less clear,with some
studies finding that higher rates of side effects, and
greater medication burden (ie,more medication and/or
more frequent dosing) related to worse adherence,
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inverse.
52,53 Interestingly, in a large cross-national
European survey,fears about future side effects (eg,fear
of toxicity) or dependence on medication were more
related to nonadherence than were experienced side
effects,which were rarely endorsed a reason for stopping
medications.
54
Provider-related predictors of adherence include the
quality of the therapeutic alliance and satisfaction with
care provided.
48 Factors involved in the alliance would
include the degree of agreement between in terms of
treatment outcomes and importance of side effects.
Another important correlate of nonadherence that has
received less attention is problems with accessing health
care and financing. It is unclear whether and to what
degree financial barriers impact treatment utilization in
bipolar disorder.
The strength of these risk factors may differ depending
on the kind of nonadherence that is being assessed.
Intentional nonadherence involves a conscious decision
not take medication,and may relate more strongly to dis-
satisfaction with treatment and lack of perceived need
for treatment.
48 Unintentional nonadherence may relate
to cognitive deficits and to lower health care literacy,and
may be of particular concern given the cognitive deficits
associated with bipolar disorder.Adherence is described
by Park and colleagues
55-57 as including a series of cogni-
tive processes:
1.Working memory in transferring data from pill-bottle
labels 
2.Prospective memory and executive functioning in orga-
nizing and planning to take medications 
3.Long-term memory in recalling medication dosage
times.
This model has been applied to adherence and interven-
tions for medically ill older adults,
57,58 although not to late-
life psychiatric disorders.Cognitive impairment has been
identified as a risk factor for nonadherence in bipolar dis-
order.
48,59 In a study of older adults prescribed antide-
pressants,cognitive impairment was the greatest risk fac-
tor for unintentional nonadherence.
60 From the larger
body of literature on cognitive abilities and adherence in
other chronic illnesses (eg,HIV),evidence suggests that
memory deficits are not the sole cognitive ability impli-
cated in nonadherence.
61 Deficits in executive function
and attention relate to worse adherence
61,62 and medica-
tion management ability.
63,64 Cognitive deficits may
reduce ability to comprehend the purposes and instruc-
tions of medications,which may also contribute to prob-
lems with adherence.
57
Interventions to enhance medication adherence in
bipolar disorder
Among therapeutic modalities for bipolar disorder,some
address adherence more centrally than others. In a
review of the effectiveness of psychotherapy for enhanc-
ing medication adherence in bipolar disorder,7 of 11 clin-
ical trials reviewed showed positive effects on medication
adherence,
65 with greater effect found for multicompo-
nent interventions that focused on medication adherence
versus interventions that covered a broad set of problems
or those that only included education.
The goal of psychosocial interventions focusing on med-
ication adherence enhancement is typically to alter atti-
tudes toward bipolar illness and need for medication,
thus targeting intentional adherence.An implicit assump-
tion is that once the participant is willing to take the med-
ication, they will be able to manage medications and
maintain adherence. However, examining the broader
spectrum of interventions that have been evaluated in
older adults with schizophrenia
66 or other chronic ill-
nesses,
67 multicomponent interventions include training
in medication management skills,as well.The following
is a description of a model to enhance adherence in bipo-
lar disorder that we have developed,which includes three
components:education,motivational interviewing,and
compensatory skills training.
Education
The primary goal is to increase knowledge about the prop-
erties of medications and awareness of the patient’s role in
managing medication.At a minimum,educational inter-
ventions should include printed information about the
basic properties of mood stabilizers, antipsychotics, and
antidepressants,such as their purposes,dosages and instruc-
tions, and factors that affect medication effectiveness.
Coupled with medication-related education,the causes and
consequences of bipolar disorder,and particularly useful
to draw parallels to other chronic medical illnesses such as
diabetes.Education should also strive to highlight the per-
sonal impacts of the illness,in order to make information
more salient to the individual.A useful method of increas-
ing personal awareness of bipolar disorder symptoms is to
have participants complete mood and life charts.
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The goal of motivational enhancement interventions is
to increase the probability of behavior change (ie,taking
medications consistently),by highlighting the advantages
of adherence, developing strategies to counteract the
drawbacks,and,in general,increasing participant activa-
tion in developing a treatment plan.A useful tool is the
“decisional balance” activity, which solicits perceived
benefits and drawbacks of taking medications, a tech-
nique commonly employed in motivational interview-
ing.
68To address the primary drawback of side effects,the
use of a side-effect tracking form may assist in recogniz-
ing side effects,and subsequently a personalized plan can
be developed to counteract chronic side effects. For
example,goal-setting with respect to behavioral strate-
gies to counteract weight gain or fatigue can be
employed.
69
Compensatory skills training
To reduce the amount of effortful cognitive processing in
daily adherence behaviors,interventions encourage con-
sistent medication taking habits and by simplifying the
act of organizing medications.Interventions in this cat-
egory are primarily intended to address unintentional
nonadherence.A wide variety of strategies are available
to increase the ease of taking medications,including med-
ication tracking forms and external reminders/tools (eg,
pillboxes,electronic medication reminders).These exter-
nal cues are best coupled with behavioral strategies that
facilitate recalling medication,including pairing activities
with medication taking,developing routines around med-
ication taking, and placing cues in the environment to
trigger medication-taking behavior.It is vital that these
strategies be personalized,and that the emphasis is on
making the process of medication taking easier and less
effortful.
In our pilot study of this intervention,which was an open
trial that included 21 participants over the age 50, we
evaluated a 12-session group intervention delivered to 6
to 8 participants with bipolar disorder at a time. The
dropout rate was 25%,with attrition mostly due to trans-
portation problems and medical comorbidities.Small to
moderate pre-post effect sizes were seen in self-reported
adherence and some depressive symptoms.These pre-
liminary results suggest that the group treatment was fea-
sible,acceptable,and produced pre-post improvements
along important dimensions,although future clinical tri-
als with objective measures of adherence and a credible
control group would be necessary to ascertain its effec-
tiveness.
Provider-level interventions
The interventions described above are all focused on
enhancing adherence by increasing knowledge, accep-
tance, and management skills in the patient. However,
there are a number of approaches to improve adherence
by changing provider behavior.These can be categorized
into attempts to:(i) increase ease of administration and (ii)
enhance the working alliance.Simplifying dosing strate-
gies by consolidation can enhance adherence and provid-
ing reminders and pillboxes.The working alliance and sat-
isfaction with treatment can be enhanced by providing
client-centered care,making effort to involve the patient
in planning medication strategies and outcomes,and defin-
ing patient values in weighing treatment options.
48,69
Emerging directions
In addition to discovering the mediators and moderators
of psychotherapy’s effectiveness in bipolar disorder,
along with broadening access to evidence-based inter-
ventions,there are a number of other modalities that are
in the earliest stages of development.
Integrative interventions addressing medical 
comorbidities
The medical burden in bipolar disorder appears to be
higher than among nonaffected individuals.
70 The con-
vergence of bipolar disorder and chronic physical ill-
nesses,such as cardiovascular (eg,diabetes) and infec-
tious diseases (eg,HIV,hepatitis) arise from a number of
shared risk factors,including unhealthy lifestyles,risk-tak-
ing behaviors,and medication side effects.
70 In addition
to increasing the burden and complexity of adherence vis
a vis higher intensity of medication management,comor-
bid medical conditions negatively impact quality of life
and health care utilization.
71 Furthermore,access to med-
ical services may be diminished in bipolar disorder.
Research identifying shared risk factors for nonadher-
ence and other outcomes in bipolar disorder,such as cog-
nitive impairment (see Moore et al in this issue,p 256),
will inform future interventions.
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Cognitive training and functional rehabilitation
In light of the cognitive deficits that have been identified
in bipolar disorder,
72 it may be that cognitive remedia-
tion,either through restorative interventions (eg,boost-
ing attention skills) or compensatory functional training
(eg, using external reminders) could be useful. These
interventions have been assessed in patients with schiz-
ophrenia.
73 Interventions that directly address specific
functional consequences of bipolar disorder,such as dif-
ficulty maintaining employment,have also been called
for.
15
Consumer-driven care
To allay some of the impracticalities associated with pro-
viding intensive psychosocial treatments,peer-provided
services may be useful in bipolar disorder.People with
bipolar disorder could be trained to deliver manualized
interventions,they could provide augmentative functions,
or could extend the availability of services beyond the
consultation of structured professionally led groups.
Given that bipolar disorder is a chronic condition,these
community-based approaches are attractive in that they
can be and are already are sustained in the community.
Mutual support interventions exist for bipolar disorder,
and are exemplified by the support groups sponsored by
the Depression and Bipolar Support Alliance
(www.dbsalliance.org).
Sequence or stepped-care based strategies
A number of recent practical clinical trials have evalu-
ated sequential treatment strategies. For example, the
National Institutes of Mental Health-funded Sequenced
Treatment Alternatives to Relieving Depression (STAR-
D) trial first administered citalopram to all participants
and then randomized unrecovered subjects to a variety
of different treatment arms.
74 Such sequenced approaches
to care mimic real world clinical decision making, and
could be applied to the study of psychotherapy for bipo-
lar disorder.The sequence of brief psychoeducation to
intensive psychotherapy in unremitted individuals could
be one logical approach to allocating psychosocial treat-
ment to people with bipolar disorder.
Conclusions
These are turbulent times in the history of the treatment
of bipolar disorder.Along with the expansion in medica-
tion options for bipolar disorder,the role of psychother-
apy as an augmentative treatment has grown from a
place of questionable utility to approaching evidence-
based care in a relatively brief period of time.There are
a number of modalities of psychosocial intervention for
bipolar disorder that have been evaluated in randomized
clinical trials, along with some emerging directions for
future psychotherapeutic approaches.There is an inade-
quate understanding about the essential ingredients of
these psychotherapeutic approaches,and little evidence
to determine which works best for which subgroups of
patients.However,addressing medication nonadherence
is a common factor in many of these modalities,and has
long been recognized as a central clinical concern in man-
aging bipolar disorder. Limited evidence suggests that
adherence can be improved with multicomponent inter-
ventions aimed at improving patient knowledge,accep-
tance,and management of pharmacotherapy,along with
enhancing participation in the treatment decision-mak-
ing process.A structured approach to the enhancement
of medication adherence should be a part of the treat-
ment regimen for all patients with bipolar disorder.While
it certainly would help if medications were more effec-
tive with fewer side effects in the treatment of bipolar
disorder,the combination of pharmacotherapy and psy-
chosocial intervention may be the most potent route to
attaining recovery.Discovering how to make evidence-
based psychosocial intervention available and palatable
to people with bipolar disorder will be a challenge for the
future. ❏
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Adherencia a las intervenciones psicosocia-
les y a la medicación en el trastorno bipolar
La investigación reciente ha señalado que las inter-
venciones psicosociales pueden tener un valioso
papel en la reducción de la considerable incapaci-
dad psicosocial asociada al trastorno bipolar. Los
ensayos controlados y randomizados de estas inter-
venciones muestran que se ha obtenido mejoría en
los síntomas, en el funcionamiento psicosocial y en
la adherencia al tratamiento. Estas intervenciones
sistemáticamente presentadas como manuales tera-
péuticos estandarizados, varían en el formato, la
duración y las bases teóricas. Todas están referidas
a aumentar la farmacoterapia, lo que representa el
estándar de tratamiento en este campo. Las moda-
lidades que han reunido el mayor soporte empírico
incluyen la terapia cognitivo conductual, la terapia
focalizada en la familia, la terapia interpersonal y
del ritmo social, y la psicoeducación. El aumento de
la adherencia a la farmacoterapia es un objetivo
terapéutico habitual, debido a la asociación entre
la falta de adherencia y la mayor frecuencia de
recaídas, hospitalizaciones y costos de salud entre
las personas con trastorno bipolar. Dada la comple-
jidad de la conducta de mala adherencia, a menudo
se requiere de intervenciones con múltiples com-
ponentes. En esta revisión se entrega una panorá-
mica de las principales aproximaciones psicotera-
péuticas - fundamentadas y basadas en la
evidencia-  para el trastorno bipolar, enfocándose
en la evaluación y el aumento de la adherencia a la
medicación.
Observance médicamenteuse et actions psy-
chosociales dans les troubles bipolaires
Des travaux récents ont montré que l’inadaptation
psychosociale importante liée aux troubles bipo-
laires pouvait être améliorée par des actions spé-
cialisées dans ce domaine.  Des études randomisées
contrôlées récentes de ces dernières ont apporté
des preuves que des améliorations sont possibles en
termes de symptômes, fonctionnement et obser-
vance thérapeutique. Ces actions, systématique-
ment présentées dans des manuels d’utilisation
standardisés, varient dans leur forme, leur durée et
leur base théorique. Toutes sont censées potentia-
liser la pharmacothérapie, base du traitement de la
maladie. Parmi les modalités les plus validées se
trouvent la thérapie cognitivo-comportementale,
la thérapie familiale, la thérapie interpersonnelle
et des rythmes sociaux et la psychoéducation.
L’objectif thérapeutique commun est une meilleure
observance médicamenteuse car sa mauvaise qua-
lité est associée à une augmentation des taux de
récidive, d’hospitalisation, des coûts de santé parmi
la population bipolaire. Compte tenu de la com-
plexité des comportements de mauvaise obser-
vance, des actions composites sont souvent néces-
saires. Dans cet article, nous proposons une mise au
point des principales approches psychothérapeu-
tiques basées sur des preuves et justifiées, en nous
centrant sur l’évaluation et l’amélioration de l’ob-
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